HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $117
Benzinga Newsdesk 9 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $80 to $117.
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $80 to $117.